1. Global tuberculosis report 2022. Geneva: World Health Organization; 2022 (
  2. Framework for collaborative action on tuberculosis and comorbidities. Geneva: World Health Organization; 2022 (
  3. The End TB Strategy. Geneva; 2015 (WHO/HTM/TB/2015.19;
  4. Resolution A/RES/73/3. Political declaration of the UN General Assembly High-Level Meeting on the fight against tuberculosis. Resolution adopted by the General Assembly on 26 September 2018. New York: United Nations; 2018 (
  5. Resolution 70/1. Transforming our world: the 2030 agenda for sustainable development. Resolution adopted by the General Assembly on 25 September 2015. New York: United Nations; 2015 (A/RES/70/1;
  6. Resolution A/RES/73/2. Political declaration of the third high-level meeting of the General Assembly on the prevention and control of non-communicable diseases. Resolution adopted by the General Assembly on 10 October 2018. New York: United Nations; 2018 (
  7. Resolution A/RES/75/284. Political declaration on HIV and AIDS: ending inequalities and getting on track to end AIDS by 2030. Resolution adopted by the General Assembly on 8 June 2021. New York: United Nations; 2021 (
  8. International Classification of Diseases, Eleventh Revision (ICD-11). Geneva: World Health Organization (WHO); 2019/2021 (, accessed 1 June, 2023).
  9. Framework on integrated, people-centred health services. Report by the Secretariat to the Sixty-ninth World Health Assembly, Geneva, 23-28 May 2016. Geneva: World Health Organization; 2016 (A69/39;
  10. WHO consolidated guidelines on tuberculosis. Module 1: prevention – tuberculosis preventive treatment. Geneva: World Health Organization; 2020 (
  11. World mental health report: Transforming mental health for all. Geneva: World Health Organization; 2022 (, accessed 28 November 2022).
  12. Doherty AM, Kelly J, McDonald C, O’Dywer AM, Keane J, Cooney J. A review of the interplay between tuberculosis and mental health. Gen Hosp Psychiatry. 2013;35:398-406. doi: 10.1016/j. genhosppsych.2013.03.018.
  13. Sweetland A, Oquendo M, Wickramaratne P, Weissman M, Wainberg M. Depression: a silent driver of the global tuberculosis epidemic. World Psychiatry. 2014;13:325-6. doi: 10.1002/wps.20134.
  14. Pachi A, Bratis D, Moussas G, Tselebis A. Psychiatric morbidity and other factors affecting treatment adherence in pulmonary tuberculosis patients. Tuberc Res Treat. 2013;2013:489865. doi: 10.1155/2013/489865.
  15. Lee G, Scuffell J, Galea JT, Shin SS, Magill E, Jaramillo E et al. Impact of mental disorders on active TB treatment outcomes: a systematic review and meta-analysis. Int J Tuberc Lung Dis. 2020;24:1279-84. doi: 10.5588/ijtld.20.0458.
  16. Oh KH, Choi H, Kim E, Kim HJ, Cho S. Depression and risk of tuberculosis: A nationwide population-based cohort study. Int J Tuberc Lung Dis. 2017;21:804-9. doi: 10.5588/ijtld.17.0038.
  17. Sweetland AC, Kritski A, Oquendo MA, Sublette ME, Norcini Pala A, Batista Silva LR et al. Addressing the tuberculosis-depression syndemic to end the tuberculosis epidemic. Int J Tuberc Lung Dis. 2017;21:852-61. doi: 10.5588/ijtld.16.0584.
  18. Hwang TJ, Wares DF, Jafarov A, Jakubowiak W, Nunn P, Keshavjee S. Safety of cycloserine and terizidone for the treatment of drug-resistant tuberculosis: a meta-analysis. Int J Tuberc Lung Dis. 2013;17:1257-66. doi: 10.5588/ijtld.12.0863.
  19. Vega P, Sweetland A, Acha J, Castillo H, Guerra D, Smith Fawzi MC et al. Psychiatric issues in the management of patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2004;8:749-59.
  20. Duko B, Bedaso A, Ayano G. The prevalence of depression among patients with tuberculosis: a systematic review and meta-analysis. Ann Gen Psychiatry. 2020;19:1-11. doi: 10.1186/s12991-020-00281-8.
  21. Alene KA, Clements ACA, McBryde ES, Jaramillo E, Lönnroth K, Shaweno D et al. Mental health disorders, social stressors, and health-related quality of life in patients with multidrug-resistant tuberculosis: A systematic review and meta-analysis. J Infect. 2018;77:357-67. doi: 10.1016/j.jinf.2018.07.007.
  22. Global tuberculosis report 2021. Geneva: World Health Organization; 2021 (, accessed 11 March, 2022).
  23. Sharma A, Machado E, Lima KVB, Suffys PN, Conceição EC. Tuberculosis drug resistance profiling based on machine learning: A literature review. Braz J Infect Dis. 2022;26:102332. doi: 10.1016/j.bjid.2022.102332.
  24. Deribew A, Tesfaye M, Hailmichael Y, Apers L, Abebe G, Duchateau L et al. Common mental disorders in TB/HIV co-infected patients in Ethiopia. BMC Infect Dis. 2010;10:201. doi: 10.1186/1471-2334-10-201.
  25. Acha J, Sweetland A, Guerra D, Chalco K, Castillo H, Palacios E. Psychosocial support groups for patients with multidrug-resistant tuberculosis: five years of experience. Glob Public Health. 2007;2:404-17. doi: 10.1080/17441690701191610.
  26. The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. Geneva: World Health Organization; 1992 (
  27. Pasha A, Siddiqui H, Ali S, Brooks MB, Maqbool NR, Khan AJ. Impact of integrating mental health services within existing tuberculosis treatment facilities. Med Access Point Care. 2021;5. doi: 10.1177/23992026211011314.
  28. Prevention of mental disorders: effective interventions and policy options – summary report / a report of the World Health Organization Dept. of Mental Health and Substance Abuse in collaboration with the Prevention Research Centre of the Universities of Nijmegen and Maastricht. Geneva: World Health Organization; 2004 (
  29. Tanimura T, Jaramillo E, Weil D, Raviglione M, Lönnroth K. Financial burden for tuberculosis patients in low- and middle-income countries: a systematic review. Eur Respir J. 2014;43:1763-75. doi: 10.1183/09031936.00193413.
  30. Uplekar M, Weil D, Lonnroth K, Jaramillo E, Lienhardt C, Dias HM et al. WHO’s new end TB strategy. Lancet. 2015;385:1799-801. doi: 10.1016/S0140-6736(15)60570-0.
  31. mhGAP Intervention Guide for mental, neurological, and substance use disorders. Geneva: World Health Organization; 2010 (
  32. mhGAP Intervention Guide for mental, neurological and substance use disorders in non-specialized health settings, Version 2.0. Geneva: World Health Organization; 2016 (
  33. The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): manual for use in primary care. Geneva: World Health Organization; 2010 (
  34. Brief Intervention: The ASSIST-linked brief intervention for hazardous and harmful substance use: Manual for use in primary care. Geneva: World Health Organization; 2010 (
  35. International standards for the treatment of drug use disorders: revised edition incorporating results of field-testing. Geneva: World Health Organization and United Nations Office on Drugs and Crime; 2020 (
  36. Guidelines for identification and management of substance use and substance use disorders in pregnancy. Geneva: World Health Organization; 2014 (
  37. Community management of opioid overdose. Geneva: World Health Organization; 2014 (
  38. Guidelines for the management of physical health conditions in adults with severe mental disorders. Geneva: World Health Organization; 2018 (
  39. Archer J, Bower P, Gilbody S, Lovell K, Richards D, Gask L et al. Collaborative care for depression and anxiety problems. Cochrane Database Syst Rev. 2012;10:CD006525. doi: 10.1002/14651858.CD006525. pub2.
  40. Integrating the prevention and control of noncommunicable diseases in HIV/AIDS, tuberculosis, and sexual and reproductive health programmes: implementation guidance. Geneva: World Health Organization; 2023 (
  41. Kroenke K, Spitzer RL, Williams JBW. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16:606-13. doi: 10.1046/j.1525-1497.2001.016009606.x.
  42. Problem management plus (PM+): individual psychological help for adults impaired by distress in communities exposed to adversity, WHO generic field-trial version 1.0. Geneva: World Health Organization; 2016 (
  43. Tol WA, Leku MR, Lakin DP, Carswell K, Augustinavicius J, Adaku A et al. Guided self-help to reduce psychological distress in South Sudanese female refugees in Uganda: a cluster randomised trial. Lancet Glob Health. 2020;8:e254-e63. doi: 10.1016/s2214-109x(19)30504-2.
  44. Epping-Jordan JE, Harris R, Brown FL, Carswell K, Foley C, García-Moreno C et al. Self-Help Plus (SH+): a new WHO stress management package. World Psychiatry. 2016;15:295-6. doi: 10.1002/wps.20355.
  45. Warth M, Kessler J, Koehler F, Aguilar-Raab C, Bardenheuer HJ, Ditzen B. Brief psychosocial interventions improve quality of life of patients receiving palliative care: A systematic review and meta-analysis. Palliative Medicine. 2019;33:332-45. doi: 10.1177/0269216318818011.
  46. Update of the Mental Health Gap Action Programme (mhGAP) guidelines for mental, neurological and substance use disorders, 2015. Geneva: World Health Organization; 2015 (
  47. Moodley N, Saimen A, Zakhura N, Motau D, Setswe G, Charalambous S et al. ‘They are inconveniencing us’ - exploring how gaps in patient education and patient centred approaches interfere with TB treatment adherence: perspectives from patients and clinicians in the Free State Province, South Africa. BMC Public Health. 2020;20:454. doi: 10.1186/s12889-020-08562-3.
  48. Spitzer RL, Kroenke K, Williams JBW, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166:1092-7. doi: 10.1001/archinte.166.10.1092.
  49. WHO operational handbook on tuberculosis. Module 4: treatment - drug-resistant tuberculosis treatment, 2022 update. Geneva: World Health Organization; 2022 (
  50. National Institute for Health and Care Excellence. Generalised anxiety disorder and panic disorder in adults: management - Clinical guideline. London; 2011 (updated 2020) (
  51. Hayward SE, Deal A, Rustage K, Nellums LB, Sweetland AC, Boccia D et al. The relationship between mental health and risk of active tuberculosis: a systematic review. BMJ Open. 2022;12:e048945. doi: 10.1136/bmjopen-2021-048945.
  52. Rehm J, Samokhvalov AV, Neuman MG, Room R, Parry C, Lonnroth K et al. The association between alcohol use, alcohol use disorders and tuberculosis (TB). A systematic review. BMC Public Health. 2009;9:450. doi: 10.1186/1471-2458-9-450.
  53. Imtiaz S, Shield KD, Roerecke M, Samokhvalov AV, Lönnroth K, Rehm J. Alcohol consumption as a risk factor for tuberculosis: meta-analyses and burden of disease. Eur Respir J. 2017;50:1700216. doi: 10.1183/13993003.00216-2017.
  54. Deiss RG, Rodwell TC, Garfein RS. Tuberculosis and illicit drug use: review and update. Clin Infect Dis. 2009;48:72-82. doi: 10.1086/594126.
  55. Global status report on alcohol and health 2018. Geneva: World Health Organization; 2018 (
  56. World Drug Report 2017. Vienna: United Nations Office on Drugs and Crime; 2017 (
  57. Grenfell P, Baptista Leite R, Garfein R, De Lussigny S, Platt L, Rhodes T. Tuberculosis, injecting drug use and integrated HIV-TB care: a review of the literature. Drug Alcohol Depend. 2013;129:180-209. doi: 10.1016/j.drugalcdep.2012.11.013.
  58. Raviglione M, Poznyak V. Targeting harmful use of alcohol for prevention and treatment of tuberculosis: a call for action. Eur Respir J. 2017;50. doi: 10.1183/13993003.00946-2017.
  59. Mlunde LB, Sunguya BF, Mbwambo JKK, Ubuguyu OS, Yasuoka J, Jimba M. Association of opioid agonist therapy with the initiation of antiretroviral therapy - a systematic review. Int J Infect Dis. 2016;46:27-33. doi: 10.1016/j.ijid.2016.03.022.
  60. Nosyk B, Min JE, Colley G, Lima VD, Yip B, Milloy MJ et al. The causal effect of opioid substitution treatment on HAART medication refill adherence. AIDS. 2015;29:965–73. doi: 10.1097/QAD.0000000000000642.
  61. Morozova O, Dvoryak S, Altice FL. Methadone treatment improves tuberculosis treatment among hospitalized opioid dependent patients in Ukraine. Int J Drug Policy. 2013;24:e91-e8. doi: 10.1016/j. drugpo.2013.09.001.
  62. Batki SL, Gruber VA, Bradley JM, Bradley M, Delucchi K. A controlled trial of methadone treatment combined with directly observed isoniazid for tuberculosis prevention in injection drug users. Drug Alcohol Depend. 2002;66:283-93. doi: 10.1016/S0376-8716(01)00208-3.
  63. Babor TF, Higgins-Biddle JC, Saunders JB, Monteiro MG. AUDIT - the Alcohol Use Disorders Identification Test: guidelines for use in primary care. Geneva: World Health Organization; 2001: 41 (
  64. Suicide worldwide in 2019: global health estimates. Geneva: World Health Organization; 2021 (
  65. LIVE LIFE: An implementation guide for suicide prevention in countries. Geneva: World Health Organization; 2021 (
  66. Thornicroft G, Sunkel C, Aliev AA, Baker S, Brohan E, el Chammay R et al. The Lancet Commission on ending stigma and discrimination in mental health. The Lancet. 2022;400:1438-80. doi: 10.1016/S0140- 6736(22)01470-2.
  67. Candy B, Jones L, Drake R, Leurent B, King M. Interventions for supporting informal caregivers of patients in the terminal phase of a disease. Cochrane Database Syst Rev. 2011:Cd007617. doi: 10.1002/14651858. CD007617.pub2.
  68. Lee JY, Kwon N, Goo GY, Cho SI. Inadequate housing and pulmonary tuberculosis: a systematic review. BMC Public Health. 2022;22:1-12. doi: 10.1186/s12889-022-12879-6.
  69. Gutwinski S, Schreiter S, Deutscher K, Fazel S. The prevalence of mental disorders among homeless people in high-income countries: An updated systematic review and meta-regression analysis. PLoS Med. 2021;18:e1003750. doi: 10.1371/journal.pmed.1003750.
  70. Jarde A, Romano E, Afaq S, Elsony A, Lin Y, Huque R et al. Prevalence and risks of tuberculosis multimorbidity in low-income and middle-income countries: a meta-review. BMJ Open. 2022;12:e060906. doi: 10.1136/ bmjopen-2022-060906.
  71. Jarde A, Ma R, Todowede OO, Latif A, Yaqoob A, Afaq S et al. Prevalence, clusters, and burden of complex tuberculosis multimorbidity in low- and middle-income countries: a systematic review and meta-analysis (unpublished). 2022. doi: 10.1101/2022.09.22.22280228

Book navigation